Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
16 avr. 2024 08h30 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced two oral presentations...
Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
10 avr. 2024 08h30 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 10, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
04 avr. 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, April 04, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
12 mars 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
05 mars 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
29 févr. 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
XEN1101 Phase 3 epilepsy program continues to progress with X-TOLE2 and X-TOLE3 in focal onset seizures and X-ACKT in primary generalized tonic-clonic seizures; completion of patient enrollment in...
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
22 févr. 2024 16h01 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its fourth...
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
08 janv. 2024 08h00 HE
|
Xenon Pharmaceuticals Inc.
Completion of Patient Enrollment in XEN1101 Phase 3 X-TOLE2 Clinical Trial in Focal Onset Seizures Anticipated in Second Half of 2024 XEN1101 Phase 3 Program in Major Depressive Disorder Planned for...
Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 08h30 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present...
Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
04 déc. 2023 16h16 HE
|
Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced the closing of its previously...